DUBLIN--(BUSINESS WIRE)--The "Vaccine Adjuvants - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
The Vaccine Adjuvants market worldwide is projected to grow by US$492.1 Million, driven by a compounded growth of 10.2%.
Particulate Adjuvants, one of the segments analyzed and sized in this study, displays the potential to grow at over 10.4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$337.2 Million by the year 2025, Particulate Adjuvants will bring in healthy gains adding significant momentum to global growth.
Representing the developed world, the United States will maintain a 11.7% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$22 Million to the region's size and clout in the next 5 to 6 years. Over US$22.9 Million worth of projected demand in the region will come from the rest of the European markets.
In Japan, Particulate Adjuvants will reach a market size of US$30.1 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 9.7% over the next couple of years and add approximately US$83.7 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.
Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific.
All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.
Competitors identified in this market include:
- Agenus, Inc.
- Avanti Polar Lipids, Inc.
- Brenntag Biosector A/S
- CSL Ltd.
- Invivogen
- Mvp Laboratories Inc.
- Novavax, Inc.
- OZ Biosciences SAS
- Seppic S.A.
- SPI Pharma
For more information about this report visit https://www.researchandmarkets.com/r/8kn802
